Skip to main content

Kolli Prasad, Jrg Laukien, Stark Thompson, Elaine Ostrander, and Andrew Carr

Premium

Spectrum Pharmaceuticals has appointed Kolli Prasad as director of the company’s research and development department. Prasad comes to the position from Hyderabad, India-based Shantha Biotechnics, where he served for 10 years as head of R&D.


Jörg Laukien has been elected as a class III director of Bruker Biosciences by the company’s board of directors. Laukien will step into the position Jan. 1. He is currently a director or president of numerous Bruker companies in the United States and Europe, and a director of Techneon.


Stark Thompson has been elected non-executive chairman of the board of Gene Logic. Thompson has served as a member of Gene Logic’s Board since February 2002, and served as president and CEO of Life Technologies from 1988–2000.


The National Human Genome Research Institute has named Elaine Ostrander as chief of its Cancer Genetics Branch, one of the seven research branches in the Division of Intramural Research. Ostrander comes to the NHGRI from the Fred Hutchinson Cancer Research Center, in Seattle. She received a BS in 1981 from the University of Washington, and a PhD in 1987 from Oregon Health & Sciences University in Portland.


Andrew Carr, former president of discovery systems for GE Healthcare, is now functioning in an advisory role within the company. Carr was replaced by Joel McComb in August. McComb's previous work experience included a position heading the primary care division of Beckman Coulter.

 

Filed under

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.